Who is sponsoring NCT04440176?

NCT04440176 is sponsored by Pfizer.

What condition does NCT04440176 study?

NCT04440176 studies Meningococcal Vaccine.

What drugs are being tested in NCT04440176?

Interventions: MenABCWY, Saline.

What is the status of NCT04440176?

NCT04440176 is currently COMPLETED.

Last reviewed 2025-01-08 · How we verify

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

NCT04440176 PHASE2 COMPLETED Results posted

This study is designed to describe the short-term immunogenicity and safety of 2 doses of Neisseria meningitidis group A, B, C, W, and Y vaccine (MenABCWY) separated by either 12 or 36 months during adolescence, and immunopersistence up to 24 months after completing 2 doses separated by a 12-month interval.

Details

Lead sponsor	Pfizer
Phase	PHASE2
Status	COMPLETED
Enrolment	309
Start date	Wed Jun 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Meningococcal Vaccine

Interventions

MenABCWY
Saline

Countries

United States